SCHEMBL7078063

SCHEMBL7078063

Cc1nn(C)c2ncc(N(C=O)C(=O)Nc3cccc(Br)c3)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPR P35270 4/20 0.40
POLB P06746 2/20 0.40
TP53 P04637 2/20 0.39
MAPT P10636 1/20 0.39
CCR2 P41597 1/20 0.39
CCR5 P51681 1/20 0.39
NR3C1 P04150 3/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
GAA P10253 2/20 0.36
TGM2 P21980 1/20 0.36
EGFR P00533 2/20 0.36
BTK Q06187 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7079006 0.88 MEN1 (0.45) SPRPOLBTP53MAPTCCR2
SCHEMBL7078734 0.87 POLB (0.41) SPRPOLBMAPTCCR2CCR5
SCHEMBL7075366 0.87 PDE4A (0.49) SPRPOLBTP53MAPTCCR2
SCHEMBL5961440 0.86 TP53 (0.47) POLBTP53MAPTCCR2CCR5
SCHEMBL7081133 0.86 NR3C1 (0.44) SPRPOLBMAPTCCR2CCR5
SCHEMBL5961572 0.85 CCR2 (0.49) SPRPOLBMAPTCCR2CCR5
SCHEMBL7074009 0.84 NR3C1 (0.48) SPRPOLBCCR2CCR5NR3C1
SCHEMBL7077952 0.84 SPR (0.48) SPRPOLBCCR2CCR5NR3C1
SCHEMBL7079264 0.84 NR3C1 (0.40) SPRPOLBCCR2CCR5NR3C1
SCHEMBL7137484 0.83 SPR (0.43) SPRPOLBMAPTCCR2CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6670364-B2 For example (1,3-dimethylpyrazolo(5,4-b)pyridin-5-yl)-N-(((4-fluorophenyl) amino)carbonyl)-carboxamide; useful in prevention or treatment of chronic or acute inflammatory or autoimmune diseases TELIK, INC. 2003-12-30 US claimed
US-20030096705-A1 Antagonists of MCP-1 function and methods of use thereof SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 2003-05-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096705-A1 Antagonists of MCP-1 function and methods of use thereof CCR2, CCR1, CCL2 SPR 430/4885POLB 3248/4885TP53 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.